
Cardiosense provides clinicians and researchers with early detection of cardiac disease by extracting predictive biomarkers from physiological waveforms. The company combines novel multi-modal sensors and multi-sensor devices with advanced signal-processing pipelines and AI-driven algorithms to mine raw biosignals for pre-symptomatic markers. Cardiosense operates as a digital biomarker platform / MedTech solution that pairs hardware sensors with proprietary software for biomarker development and personalized therapy enablement. Its technology is aimed at healthcare providers, clinical researchers, and life‑science partners working on cardiac disease detection and treatment.

Cardiosense provides clinicians and researchers with early detection of cardiac disease by extracting predictive biomarkers from physiological waveforms. The company combines novel multi-modal sensors and multi-sensor devices with advanced signal-processing pipelines and AI-driven algorithms to mine raw biosignals for pre-symptomatic markers. Cardiosense operates as a digital biomarker platform / MedTech solution that pairs hardware sensors with proprietary software for biomarker development and personalized therapy enablement. Its technology is aimed at healthcare providers, clinical researchers, and life‑science partners working on cardiac disease detection and treatment.
Founded / HQ: May 2020 — Chicago, IL
Product: CardioTag™ — a medical‑grade multimodal wearable that measures SCG, PPG, and ECG
Clinical / regulatory: FDA Breakthrough Device designation (algorithm, Feb 2022); FDA 510(k) clearance for CardioTag (announced Jul 2025)
Funding: Series A $15.1M (Dec 8, 2022)
Clinical validation: SEISMIC‑HF clinical study program (published / validation efforts)
Early detection and management of cardiac disease, including heart failure and hemodynamic instability.
2020
Hospitals and Health Care
USD 15,100,000
Deal reported 6 investors for the round
“Backed in Series A by venture investors including Broadview Ventures, Hatteras Venture Partners, and OSF Ventures”
| Company |
|---|
Cardiosense is a rapidly growing, venture-backed medical AI company that is redefining how we detect, monitor, and manage heart disease. We're developing novel wearable sensors and advanced machine learning algorithms that translate raw physiological signals into clinically actionable, digital biomarkers used to detect early signs of cardiac worsening, guide personalized therapy, and improve patient outcomes.
Our team brings together experts in data science, biosignal analysis, and medicine united by a common mission to identify and combat preventable cardiac disease. Cardiosense's solutions are built on over a decade of clinical research and we continue to collaborate with the world's leading academic institutions to introduce the next generation of cardiac monitoring and disease management.
ABOUT THE ROLE: The Operations and Quality Intern is an undergraduate level, hands on role supporting Cardiosense’s Quality and Operations functions within a regulated medical device environment. This position is designed for a student interested in how quality systems, operational processes, and compliance requirements support the execution of medical device programs.
The intern will support quality documentation and systems, assist with operational workflows, observe and administratively support one of Cardiosense’s device programs from an operations and quality perspective, and contribute to light HR related projects as needed.
WHAT YOU'LL BE DOING: Quality and Compliance Support
Strategic Initiatives Support
Human Resources Support
QUALIFICATIONS:
PREFERRED:
COMPENSATION AND ACADEMIC CREDIT:
Cardiosense is an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, ethnicity, religion, disability status, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status.